Sanjeev Mariathasan

Kaiser Permanente San Francisco Medical Center

Full Professor(heuristic)

Cancer Immunotherapy and Biomarkers · Oncology

h-index56

i10-index99

Publications242

Citations34,453

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 85

Figure S2 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2026-06-17
Figure S1 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2026-06-17
Figure S3 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2026-06-17
Figure S4 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
2026-06-17
Supplementary Table 1 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026-06-01
Data from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026-06-01
Figure S16 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Figure S2 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Supplementary Figure 7 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026-06-01
Supplementary Figure 4 from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026-06-01
Tables S1-S4 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Figure S6 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Figure S13 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Figure S11 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Supplementary Methods from The Hippo Pathway Is Dysregulated in Cancer-Associated Fibroblasts in Anti–PD-L1–Resistant Cancer
2026-06-01
Figure S15 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Figure S9 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Figure S5 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Figure S14 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01
Figure S3 from A Tumor-Promoting Inflammatory <i>SPP1</i><sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
2026-06-01

Open author page on OpenAlex →